Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist approved by the FDA specifically for blood sugar control in adults with type 2 diabetes. While the medication has gained attention for its weight-loss effects, the original FDA approval did not include weight management as an official indication. PlexusDx provides access to compounded semaglutide through licensed 503A pharmacies, offering patients a transparent, affordable path to GLP-1 therapy without the brand-name markup or insurance barriers.
The FDA Approval Status of Ozempic for Weight Loss
Ozempic received FDA clearance in 2017 for blood glucose management in type 2 diabetes patients. The approval was based on clinical trials demonstrating that semaglutide reduced HbA1c levels and improved cardiovascular outcomes in diabetic populations. Weight loss was observed as a secondary benefit in these diabetes studies, with participants losing an average of 4–7 pounds over 30 weeks. However, this weight reduction occurred because semaglutide affects hormones that regulate appetite and satiety, not because the drug was designed or tested primarily for obesity treatment.
A separate medication, Wegovy (also semaglutide but at different doses), received FDA approval in 2021 specifically for chronic weight management in adults with obesity or overweight conditions. This distinction means Ozempic carries the diabetes label, while Wegovy carries the weight-loss label—even though the active compound is identical. Off-label prescribing by physicians remains common in clinical practice, but patients should understand that Ozempic's official indication does not list weight loss as an approved use.
How Semaglutide Works for Weight Management
Semaglutide binds to GLP-1 receptors located in the brain, digestive tract, and pancreas. This activation signals fullness to the hypothalamus, reducing hunger drive and food cravings. The medication also slows gastric emptying, meaning food stays in the stomach longer, extending the feeling of satiety between meals. Clinical trial data shows that patients on higher-dose semaglutide (2.4 mg weekly) experience an average weight loss of 15–22% of baseline body weight over 68 weeks when combined with lifestyle modifications.
GLP-1 receptor agonists also improve insulin secretion in response to blood glucose rises, stabilizing blood sugar throughout the day. This dual mechanism—appetite suppression plus metabolic improvement—explains why semaglutide produces sustained weight reduction rather than temporary water weight loss. The medication's effects depend partly on individual genetic variations in the GLP1R gene and related metabolic pathways, which PlexusDx maps through its Precision Peptide Genetic Test to predict individual response likelihood.
Off-Label Prescribing and Clinical Practice Realities
Physicians have legal authority to prescribe FDA-approved medications for indications beyond their labeled use, a practice called off-label prescribing. Many weight-loss clinics and telehealth providers have prescribed Ozempic off-label for obesity management, particularly as demand for GLP-1 therapy surged following media coverage of celebrity weight-loss results. This practice is ethically permissible when the prescriber believes evidence supports efficacy and informs the patient of the off-label status. However, off-label Ozempic prescriptions often come at premium prices because they route through diabetes-focused supply chains designed for insurance billing.
PlexusDx operates differently by offering compounded semaglutide injections from licensed 503A pharmacies, which produce pharmaceutical-grade preparations at transparent, flat monthly rates. Patients receive the same active ingredient without the brand-name premium or insurance requirement. The compounding model allows PlexusDx to serve all 50 states and make GLP-1 therapy accessible to patients who lack insurance coverage or prefer cash-pay options.
PlexusDx Compounded Semaglutide vs. Brand-Name Ozempic
PlexusDx Semaglutide Injection starts at $149 per month across all dose levels, adhering to the principle that dose increases do not trigger price increases. This pricing model contrasts sharply with traditional pharmacy models, where patients on Ozempic may face escalating copays as their doctor titrates them to higher doses. Compounded semaglutide from 503A facilities meets USP standards for purity, potency, and sterility, ensuring pharmaceutical quality without the brand markup. All medications from PlexusDx are produced by licensed 503A compounding pharmacies, never 503B outsourcing facilities, which provides additional regulatory oversight and traceability.
Patients can pay with HSA or FSA funds when choosing PlexusDx Compounded Semaglutide, adding a tax-advantaged savings layer. No membership fee, no insurance requirement, and no prior authorization delays characterize the PlexusDx experience. For individuals exploring whether semaglutide matches their metabolic profile, PlexusDx also offers the Precision Peptide Genetic Test ($99 add-on after the first month) to assess individual variations in GLP1R, GIPR, FTO, and MC4R genes—pathways directly linked to GLP-1 response variability.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic officially approved by the FDA for weight loss?
No. Ozempic carries an FDA indication for type 2 diabetes only, approved in 2017. Wegovy, a separate semaglutide product, received FDA approval in 2021 for chronic weight management. Physicians may prescribe Ozempic off-label for weight loss, but this use falls outside the official approved indication.
How much weight do people typically lose on semaglutide?
Clinical trials of higher-dose semaglutide (2.4 mg weekly) show average weight loss of 15–22% of baseline body weight over 68 weeks when combined with diet and exercise changes. Results vary based on individual factors, including genetics, adherence, and lifestyle modifications.
Why is PlexusDx Semaglutide more affordable than Ozempic?
PlexusDx sources compounded semaglutide from licensed 503A pharmacies, bypassing brand-name markups and insurance middleman costs. The flat $149/month pricing means dose increases do not trigger higher bills. Patients also avoid insurance requirements, prior authorizations, and membership fees—paying a transparent monthly rate instead.
Are there side effects I should expect from semaglutide injections?
Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and temporary as the body adjusts. Serious but rare risks include pancreatitis and gallbladder issues. Patients with personal or family history of medullary thyroid cancer should not use GLP-1 medications.
What does the PlexusDx Precision Peptide Genetic Test measure?
The test analyzes 14 metabolic pathways and 49 peptides linked to GLP-1 response, measuring variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313). These genetic insights predict how effectively your body responds to semaglutide or tirzepatide, personalizing your treatment plan.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Much Is Each Ozempic Shot
Beyond Weight Loss: Does Ozempic Help With Anxiety and ADHD?